JNJJohnson & Johnson
$261.45+53% 1Y
$261.45
$171.2152 weeks$278.28
JNJ in its own filings
Nothing in JNJ's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
599
Events found in the filings · across 3,371 filings · the record starts in 1994
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 4, 2026
Most recent filing · Form 8-K
- Record starts
- Mar 10, 1994
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Oct 13, 2026
- Security removed from listing or deregistered4 occurrences · usually a matured note or preferred class, not the common shares
- 2024-11-06
- Material impairment2 occurrences
- 2007-11-30
- SEC comment-letter activity59 occurrences
- 2025-05-02
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 4, 2026On August 4, 2026, the Company announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine and member of the Executive Committee effective September 1, 2026.Director or officer change · Form 8-K
- Jul 29, 2026J&J Global Media Relations.Regulation FD disclosure · press release
- Jul 28, 2026Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation.Regulation FD disclosure · press release
- Jul 15, 2026Johnson & Johnson reports Q2 2026 results, raises 2026 outlook.Earnings release · press release
- Apr 14, 2026At the new rate, the indicated dividend on an annual basis is $5.36 per share compared to the previous rate of $5.20 per share. The next quarterly dividend is payable on June 9, 2026 to shareholders of record at the close of business on May 26, 2026.Earnings release · Form 8-K
- Jan 21, 2026Johnson & Johnson reports Q4 and Full-Year 2025 results.Earnings release · press release
- Oct 14, 2025Johnson & Johnson reports Q3 2025 results; raises 2025 sales outlook.Earnings release · press release
- Sep 9, 2025On September 8, 2025, Johnson & Johnson (the Company) announced that John Morikis was elected to the Board of Directors. The Board has determined that Mr. Morikis satisfies the applicable independence requirements of the NYSE Listed Company Manual.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Drug Manufacturers, General
The closest names by size in the same industry